Dormuth CR - Search Results

1

Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications.

Dormuth CR, Kim JD, Fisher A, Piszczek J, Kuo IF. Dormuth CR, et al. JAMA Netw Open. 2023 Oct 2;6(10):e2336678. doi: 10.1001/jamanetworkopen.2023.36678. JAMA Netw Open. 2023. PMID: 37782496 Free PMC article.

2

Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report.

Fisher A, Kim JD, Dormuth CR. Fisher A, et al. Among authors: dormuth cr. Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):803-810. doi: 10.1002/pds.5008. Epub 2020 May 28. Pharmacoepidemiol Drug Saf. 2020. PMID: 32463156

3

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study.

Fisher A, Kim JD, Dormuth CR. Fisher A, et al. Among authors: dormuth cr. CMAJ Open. 2022 Feb 15;10(1):E109-E118. doi: 10.9778/cmajo.20200319. Print 2022 Jan-Mar. CMAJ Open. 2022. PMID: 35168933 Free PMC article.

4

Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.

Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR. Fisher A, et al. Among authors: dormuth cr. PLoS One. 2014 Aug 20;9(8):e105193. doi: 10.1371/journal.pone.0105193. eCollection 2014. PLoS One. 2014. PMID: 25141123 Free PMC article.

5

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort.

Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman HJ, Dormuth CR. Fisher A, et al. Among authors: dormuth cr. BMJ Open. 2014 Sep 30;4(9):e005532. doi: 10.1136/bmjopen-2014-005532. BMJ Open. 2014. PMID: 25270855 Free PMC article.

6

Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia.

Fisher A, Carney G, Bassett K, Maclure KM, Dormuth CR. Fisher A, et al. Among authors: dormuth cr. Pharmacoepidemiol Drug Saf. 2019 Aug;28(8):1067-1076. doi: 10.1002/pds.4804. Epub 2019 Jul 3. Pharmacoepidemiol Drug Saf. 2019. PMID: 31267629 Free PMC article.

7

A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.

Dormuth CR, Fisher A, Carney G. Dormuth CR, et al. Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):796-802. doi: 10.1002/pds.4957. Epub 2020 Jan 8. Pharmacoepidemiol Drug Saf. 2020. PMID: 31914214

8

Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort.

Dormuth CR, Winquist B, Fisher A, Wu F, Reynier P, Suissa S, Dahl M, Ma Z, Lu X, Zhang J, Raymond CB, Filion KB, Platt RW, Moriello C, Paterson JM; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Dormuth CR, et al. JAMA Netw Open. 2021 Apr 1;4(4):e215329. doi: 10.1001/jamanetworkopen.2021.5329. JAMA Netw Open. 2021. PMID: 33890993 Free PMC article.

9

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia.

Fisher A, Kim JD, Carney G, Dormuth C. Fisher A, et al. BMC Rheumatol. 2022 Jan 27;6(1):5. doi: 10.1186/s41927-021-00235-x. BMC Rheumatol. 2022. PMID: 35081991 Free PMC article.

10

The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine.

Fisher A, Kim JD, Dormuth C. Fisher A, et al. Clin Ther. 2022 Jul;44(7):957-970.e12. doi: 10.1016/j.clinthera.2022.05.003. Epub 2022 Jun 10. Clin Ther. 2022. PMID: 35691731

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

111 results

Search Page